Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) CFO David Parrot purchased 2,666 shares of the company’s stock in a transaction that occurred on Thursday, July 23rd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the purchase, the chief financial officer directly owned 1,333 shares in the company, valued at $19,995. This trade represents a -200.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Scribe Therapeutics Price Performance
Shares of SCTX stock opened at $18.36 on Thursday. Scribe Therapeutics Inc. has a 12 month low of $17.31 and a 12 month high of $25.49.
Further Reading
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
